Trillium Therapeutics Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
33
- Latest Deal Type
-
M&A
- Financing Rounds
-
10
- Investments
-
3
Trillium Therapeutics General Information
Description
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.
Contact Information
Website
www.trilliumtherapeutics.comCorporate Office
- 2488 Dunwin Drive
- Mississauga, Ontario L5L 1J9
- Canada
Corporate Office
- 2488 Dunwin Drive
- Mississauga, Ontario L5L 1J9
- Canada
Trillium Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Trillium Therapeutics Comparisons
Industry
Financing
Details
Trillium Therapeutics Competitors (11)
One of Trillium Therapeutics’s 11 competitors is Coherus Biosciences, a Formerly VC-backed company based in Redwood City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Coherus Biosciences | Formerly VC-backed | Redwood City, CA | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Biogen | Formerly VC-backed | Cambridge, MA | ||||
| Roche | Corporation | Basel, Switzerland |
Trillium Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Trillium Therapeutics Patents
Trillium Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-6495548-B2 | Computer-implemented encryption method for improving computer network, terminal, system and computer-readable medium for them | Inactive | 18-Sep-2015 | ||
| JP-2018527856-A | Computer-implemented encryption method for improving computer network, terminal, system and computer-readable medium for them | Active | 18-Sep-2015 | ||
| EP-2178554-A1 | Treating or ameliorating a neuroinflammatory or demyelinating disorder with prolactin and interferon-ß | Inactive | 20-Jul-2007 | ||
| JP-2010138202-A | Dosing regimen for lh(luteinizing hormone) or hcg(human chorionic gonadotropin) and epo(erythropoietin)for treating neurodegenerative disease | Pending | 17-Mar-2006 | ||
| JP-2010138203-A | Continuously dosing regimen for neural stem cell proliferating agent and neural stem cell differentiating agent | Pending | 17-Mar-2006 | A61K38/1816 |
Trillium Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Trillium Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Trillium Therapeutics Acquisitions (3)
Trillium Therapeutics’s most recent deal was a Merger/Acquisition with Fluorinov Pharma for . The deal was made on 27-Jan-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Fluorinov Pharma | 27-Jan-2016 | Merger/Acquisition | Drug Discovery | ||
| Trillium Therapeutics (acquired 2013) | 09-Apr-2013 | Merger/Acquisition | Biotechnology | ||
| Stem Cell Therapeutics | 12-Feb-2013 | Merger/Acquisition | Biotechnology |
Trillium Therapeutics FAQs
-
When was Trillium Therapeutics founded?
Trillium Therapeutics was founded in 2004.
-
Where is Trillium Therapeutics headquartered?
Trillium Therapeutics is headquartered in Mississauga, Canada.
-
What is the size of Trillium Therapeutics?
Trillium Therapeutics has 33 total employees.
-
What industry is Trillium Therapeutics in?
Trillium Therapeutics’s primary industry is Biotechnology.
-
Is Trillium Therapeutics a private or public company?
Trillium Therapeutics is a Private company.
-
What is the current valuation of Trillium Therapeutics?
The current valuation of Trillium Therapeutics is .
-
What is Trillium Therapeutics’s current revenue?
The current revenue for Trillium Therapeutics is .
-
How much funding has Trillium Therapeutics raised over time?
Trillium Therapeutics has raised $223M.
-
Who are Trillium Therapeutics’s investors?
Deerfield Management, Frazier Healthcare Partners, HSMR Advisors, New Enterprise Associates, and Nexus Life Science Partners are 5 of 11 investors who have invested in Trillium Therapeutics.
-
Who are Trillium Therapeutics’s competitors?
Coherus Biosciences, AbbVie, Bristol-Myers Squibb, Biogen, and Roche are some of the 11 competitors of Trillium Therapeutics.
-
When was Trillium Therapeutics acquired?
Trillium Therapeutics was acquired on 17-Nov-2021.
-
Who acquired Trillium Therapeutics?
Trillium Therapeutics was acquired by Pfizer (Pharmaceuticals).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
